Beta Bionics, Inc. (BBNX)
NASDAQ: BBNX · Real-Time Price · USD
10.08
-0.57 (-5.35%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Beta Bionics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Beta Bionics stock have an average target of 23.8, with a low estimate of 14 and a high estimate of 40. The average target predicts an increase of 136.11% from the current stock price of 10.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Beta Bionics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 12 | 12 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $25 → $24 | Buy | Maintains | $25 → $24 | +138.10% | Apr 22, 2026 |
| Stifel | Stifel | Strong Buy Maintains $22 → $20 | Strong Buy | Maintains | $22 → $20 | +98.41% | Apr 22, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $25 → $18 | Strong Buy | Maintains | $25 → $18 | +78.57% | Apr 15, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $23 → $20 | Strong Buy | Maintains | $23 → $20 | +98.41% | Apr 9, 2026 |
| Stifel | Stifel | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | +118.25% | Feb 18, 2026 |
Financial Forecast
Revenue This Year
135.24M
from 100.25M
Increased by 34.90%
Revenue Next Year
182.07M
from 135.24M
Increased by 34.63%
EPS This Year
-1.95
from -1.81
EPS Next Year
-1.96
from -1.95
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 141.5M | 203.7M | |||||
| Avg | 135.2M | 182.1M | |||||
| Low | 127.5M | 156.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 41.2% | 50.6% | |||||
| Avg | 34.9% | 34.6% | |||||
| Low | 27.2% | 15.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.55 | -1.19 | |||
| Avg | -1.95 | -1.96 | |||
| Low | -2.28 | -2.75 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.